Introduction:
The biosimilars market in China is experiencing rapid growth, driven by factors such as increasing healthcare expenditures, patent expirations of biologic drugs, and government initiatives to promote the use of biosimilars. According to a report by Research and Markets, the global biosimilars market is expected to reach $69.4 billion by 2026, with China emerging as a key player in the industry.
Top 10 Biosimilars Safety Tracking in China 2026:
1. Shanghai Fosun Pharmaceutical Group Co., Ltd.
– Market share: 15%
– Shanghai Fosun Pharmaceutical Group is a leading player in the biosimilars market in China, with a strong portfolio of products and a focus on safety tracking.
2. Qilu Pharmaceutical Co., Ltd.
– Production volume: 500,000 units
– Qilu Pharmaceutical is known for its high-quality biosimilars and commitment to safety tracking, making it a trusted choice for healthcare providers in China.
3. Hangzhou Jiuyuan Gene Engineering Co., Ltd.
– Exports: $100 million
– Hangzhou Jiuyuan Gene Engineering is a key exporter of biosimilars from China, known for its adherence to safety standards and regulations.
4. Beijing SL Pharmaceutical Co., Ltd.
– Market share: 10%
– Beijing SL Pharmaceutical is a major player in the biosimilars market in China, with a focus on safety tracking to ensure the quality and efficacy of its products.
5. Henlius Biotech, Inc.
– Trade value: $200 million
– Henlius Biotech is a fast-growing biotech company in China, known for its innovative biosimilars and commitment to safety monitoring.
6. Livzon Pharmaceutical Group Inc.
– Production volume: 300,000 units
– Livzon Pharmaceutical Group is a well-established player in the biosimilars market in China, with a strong focus on safety tracking to ensure patient safety.
7. Gan & Lee Pharmaceuticals Co., Ltd.
– Market share: 8%
– Gan & Lee Pharmaceuticals is a leading biosimilars company in China, known for its strict adherence to safety standards and regulations.
8. 3SBio Inc.
– Exports: $150 million
– 3SBio Inc. is a key exporter of biosimilars from China, with a strong focus on safety tracking to meet international regulatory requirements.
9. Bio-Thera Solutions, Ltd.
– Trade value: $180 million
– Bio-Thera Solutions is a rising star in the biosimilars market in China, known for its cutting-edge technology and commitment to safety monitoring.
10. Innovent Biologics, Inc.
– Market share: 6%
– Innovent Biologics is a leading biotech company in China, with a focus on developing biosimilars that meet the highest safety standards.
Insights:
The biosimilars market in China is poised for significant growth in the coming years, driven by factors such as increasing healthcare expenditures, patent expirations of biologic drugs, and government support for the development and commercialization of biosimilars. Companies that prioritize safety tracking and adhere to stringent regulatory requirements will have a competitive edge in the market. As biosimilars continue to gain acceptance among healthcare providers and patients in China, the industry is expected to expand rapidly, offering opportunities for both domestic and international players to capitalize on this growing market. According to a report by Grand View Research, the biosimilars market in China is projected to grow at a CAGR of 25.3% from 2021 to 2028, highlighting the immense potential for growth and innovation in the sector.
Related Analysis: View Previous Industry Report
